Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
7.215 USD | -1.03% | -4.58% | -40.09% |
04-30 | Wells Fargo Cuts Price Target on Accolade to $10 From $12, Maintains Equalweight Rating | MT |
04-26 | Morgan Stanley Trims Accolade's Price Target to $12 From $13, Maintains Equal Weight Rating | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-40.09% | 571M | |
+20.68% | 84.31B | |
-29.18% | 69.9B | |
+9.65% | 29.06B | |
-8.82% | 17.38B | |
+2.14% | 17.01B | |
+0.51% | 15.35B | |
+6.75% | 12.91B | |
+68.69% | 12.47B | |
+6.43% | 12.26B |
- Stock Market
- Equities
- ACCD Stock
- News Accolade, Inc.
- Transcript : Accolade, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 01